Franc Gay talks about the Forte trial, a phase III clil trial for newly diagnosed multiple myeloma, at ASH 2018.
Contents:
- FRANC GAY, MD, ON THE FORTE TRIAL: TRIPLET THERAPY FOR NEWLY DIAGNOSED MULTIPLE MYELOMA
- DR. GAY DISCS THE EFFICY DATA OM THE FORTE TRIAL MYELOMA
FRANC GAY, MD, ON THE FORTE TRIAL: TRIPLET THERAPY FOR NEWLY DIAGNOSED MULTIPLE MYELOMA
Franc Gay, MD, PhD, hematologist, Myeloma Un, Divisn of Hematology, Azienda Ospedaliero Universaria Ctà lla Salute e lla Scienza, discs the updated efficy data om the FORTE trial of patients wh newly-diagnosed multiple myeloma. * gay forte trial *
Gay et al.
FigureDisclosurGay:Amgen: Honoraria, Membership on an enty's Board of Directors or advisory mte; Takeda: Honoraria, Membership on an enty's Board of Directors or advisory mte; Bristol-Myers Squibb: Honoraria, Membership on an enty's Board of Directors or advisory mte; Roche: Membership on an enty's Board of Directors or advisory mte; GSK: Membership on an enty's Board of Directors or advisory mte; AbbVie: Membership on an enty's Board of Directors or advisory mte; Adaptive: Membership on an enty's Board of Directors or advisory mte; Seattle Geics: Membership on an enty's Board of Directors or advisory mte; Onpeptis: Membership on an enty's Board of Directors or advisory mte; Janssen: Honoraria, Membership on an enty's Board of Directors or advisory mte; Celgene: Honoraria, Membership on an enty's Board of Directors or advisory mte. Updated rults om the FORTE trial were recently published Lancet Onlogy by Franc Gay et al.
DR. GAY DISCS THE EFFICY DATA OM THE FORTE TRIAL MYELOMA
Franc Gay, Universy of Toro, Toro, IT, prents a risk analysis update om the FORTE trial of rfilzomib + lenalidomi + xamethasone (KRd) wh, or whout, transplantatn * gay forte trial *
*Adapted om Gay, et al. *Adapted om Gay et al.
*Data om Gay, et al. Gay F, Mto P, Rota-Slabri D, et al. Gay F, Ma R, Rota-Slabriet D, al.
* gay forte trial *
Out of the FORTE trial, Gay and lleagu reported a PFS rate of 62% after four years HR patients treated wh upont KRd, ASCT, and KR or R matenance, however g a broad fn of HR acuntg for more than 50% of the trial populatn [9]. Ma R, Mto P, Rota-Slabri D, Paris L, Gamberi B, Palmas A, Aquo S, Fabriis P, Giuliani N, De Rosa L, Gozzetti A, Celli C, Bertami L, Capra A, Oddolo D, Vcelli ID, Ronni S, Pavone V, Psta N, Cea M, Froni F, Ballanti S, Grasso M, Zamagni E, Belotti A, Bocdoro M, Gay F. Cavo M, Gay F, Beksac M, Pantani L, Petcci MT, Dimopoulos MA, Dozza L, van r Holt B, Zweegman S, Oliva S, van r Veln VHJ, Zamagni E, Palumbo GA, Patriar F, Montef V, Galli M, Maisnar V, Gamberi B, Hansson M, Belotti A, Pour L, Ypma P, Grasso M, Croockew A, Ballanti S, Offidani M, Vcelli ID, Zambello R, Liberati AM, Anrsen NF, Broijl A, Troia R, Pasrella A, Benevolo G, Lev MD, Bos G, Ludwig H, Aquo S, Morelli AM, Wu KL, Boersma R, Hajek R, Durian M, von m Borne PA, Carava di Torto T, Zanr T, Drisen C, Specchia G, Waage A, Gimsg P, Mellqvist UH, van Marwijk Kooy M, Mnema M, Mandigers C, Cao AM, Palmas A, Carvalho S, Spencer A, Bocdoro M, Sonneveld P.
Dr Franc Gay speaks to encer about the survival analysis of newly diagnosed transplant-eligible multiple myeloma patients the randomised Forte trial * gay forte trial *
Gay F, Oliva S, Petcci MT, Conticello C, Catalano L, Corradi P, Sislchi A, Magarotto V, Pour L, Carella A, Malfano A, Petrò D, Evangelista A, Spada S, Psta N, Omedè P, Campbell P, Liberati AM, Offidani M, Ria R, Puli S, Patriar F, Hajek R, Spencer A, Bocdoro M, Palumbo A.